文献速递针灸推拿中医康复

侵入性针灸治疗化疗相关恶心呕吐:系统评价再评价

Acupuncture for chemotherapy-induced nausea and vomiting: An umbrella review of systematic reviews.
PubMed 文献 · Complement Ther Med · 2026-09-23

该伞形综述汇总8篇系统评价/Meta分析,并对其中的41项原始随机对照试验(3843例患者)重新做Meta分析。结果显示侵入性针灸对延迟性化疗相关恶心呕吐(CINV)的有效率和完全缓解率有改善,并改善KPS与FLIE评分、降低血清5-HT水平,但纳入研究的多数结局证据确定性为低或极低。

要点

  • 针灸可能改善延迟性CINV的有效率与完全缓解率
  • 可改善KPS及化疗结束后的FLIE评分并降低血清5-HT
  • 现有证据质量偏低,结论需谨慎看待

核心结论

  • 侵入性针灸可能对延迟性化疗相关恶心呕吐有益,但现有证据的确定性受研究方法学局限限制,仍需大样本、严格设计的随机对照试验确认。

研究设计与样本

  • 伞形系统评价:系统检索Cochrane Library、Embase、PubMed、Web of Science、CBM、VIP、CNKI和万方数据库,检索时间自建库至2025年11月9日。
  • 纳入8篇系统评价/Meta分析,采用AMSTAR 2、PRISMA清单、ROBIS和GRADE分别评估方法学质量、报告质量、偏倚风险与证据确定性。
  • 对纳入系统评价中识别的原始随机对照试验重新进行Meta分析,共纳入41项原始随机对照试验、3843例患者。

主要发现

  • 延迟性CINV有效率:18项随机对照试验,P < 0.001,RR = 1.26,95% CI:1.17-1.34,I² = 49%。
  • 延迟性CINV完全缓解率:11项随机对照试验,P = 0.002,RR = 1.32,95% CI:1.10-1.57,I² = 55%。
  • KPS评分:5项随机对照试验,P < 0.001,MD = 5.16,95% CI:3.15-7.16,I² = 52%。
  • 化疗结束后FLIE评分:3项随机对照试验,P < 0.001,MD = 5.50,95% CI:2.64-8.35,I² = 68%。
  • 血清5-HT水平:4项随机对照试验,P < 0.001,MD = -27.65,95% CI:-39.24至-16.06,I² = 0%。

关键数值与推荐

  • 纳入的8篇系统评价/Meta分析方法学质量总体偏低,GRADE评估显示多数报告结局的证据确定性为低或极低。
  • 重新Meta分析中,侵入性针灸对延迟性CINV有效率的RR = 1.26(95% CI:1.17-1.34),完全缓解率RR = 1.32(95% CI:1.10-1.57)。
  • KPS评分MD = 5.16(95% CI:3.15-7.16),FLIE评分MD = 5.50(95% CI:2.64-8.35),血清5-HT水平MD = -27.65(95% CI:-39.24至-16.06)。

临床怎么用

  • 对接受化疗并出现延迟性恶心呕吐的患者,可在综合止吐方案基础上考虑联合侵入性针灸以改善症状控制。
  • 针灸可能同时改善患者体力状况(KPS)与化疗后生活质量(FLIE),可作为支持治疗的一部分评估使用。
  • 与患者沟通时应说明现有证据确定性偏低,针灸疗效仍需高质量试验验证。

局限性

  • 纳入的系统评价/Meta分析方法学质量总体偏低,GRADE证据确定性多为低或极低。
  • 原始随机对照试验在设计、样本量与结局报告方面存在局限,可能影响合并结果的可靠性。
  • 重新Meta分析中部分结局纳入的随机对照试验数量较少(如FLIE仅3项),异质性存在(I²最高68%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This umbrella systematic review aimed to evaluate the efficacy of invasive acupuncture for chemotherapy-induced nausea and vomiting (CINV) by synthesizing existing systematic reviews and meta-analyses and conducting a renewed meta-analysis of primary randomized controlled trials (RCTs). METHODS: We systematically searched the Cochrane Library, Embase, PubMed, Web of Science, China Biology Medicine (CBM), VIP Chinese Scientific Journals Database (VIP), China National Knowledge Infrastructure (CNKI), and Wanfang Data Knowledge Service Platform from inception to November 9, 2025, for SRs/MAs evaluating invasive acupuncture for CINV. The methodological quality, reporting quality, and risk of bias of the included SRs/MAs were assessed using A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2), the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, and Risk of Bias in Systematic Reviews (ROBIS), respectively. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the certainty of evidence for the outcomes reported in the included SRs/MAs. A renewed meta-analysis of the primary RCTs identified from these SRs/MAs was subsequently conducted to evaluate the efficacy of invasive acupuncture for CINV. Statistical heterogeneity, sensitivity, and publication bias were also assessed. RESULTS: Eight SRs/MAs were included. Their methodological quality was generally low, and the GRADE assessment indicated low or very low certainty of evidence for most reported outcomes. The renewed meta-analysis included 41 primary RCTs involving 3843 patients. Invasive acupuncture showed significant benefits for delayed CINV, improving the effective rate (18 RCTs, P < 0.001, RR = 1.26, 95% CI: 1.17-1.34, I² = 49%) and complete response rate (11 RCTs, P = 0.002, RR = 1.32, 95% CI: 1.10-1.57, I² = 55%). It also improved Karnofsky Performance Status (KPS) scores (5 RCTs, P < 0.001, MD = 5.16, 95% CI: 3.15-7.16, I² = 52%) and Functional Living Index-Emesis (FLIE) scores after chemotherapy completion (3 RCTs, P < 0.001, MD = 5.50, 95% CI: 2.64-8.35, I² = 68%) and reduced serum 5-HT levels (4 RCTs, P < 0.001, MD = -27.65, 95% CI: -39.24 to -16.06, I² = 0%). CONCLUSION: Invasive acupuncture may be beneficial for delayed CINV. However, the certainty of the current evidence is limited by the methodological limitations of the available studies. Further large-scale, rigorously designed RCTs with adequate sample sizes are needed to confirm its efficacy for CINV.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Cao J, Wu J, Bi Z, et al. Acupuncture for chemotherapy-induced nausea and vomiting: An umbrella review of systematic reviews. Complement Ther Med. 2026. PMID: 42772702. doi:10.1016/j.ctim.2026.103438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。